semaglutide and statins Effect of oral on remnant-like lipoprotein cholesterol in patients with ischemic heart disease receiving statin therapy | Diabetology International 🫀 How Artery Plaque Changes

In this trial involving over 17,000 participants with preexisting cardiovascular conditions but without diabetes, semaglutide was associated with a 15% reduction in major adverse cardiovascular events over approximately 40 months

In those that stop taking the medications, rebound weight gain is very common

Participants in one trial lost around 15% of their body weight over 72 weeks, with many losing more than 20% at a higher dosage

They cannot predict when they will reach full supply, but encourage patients to try other local pharmacies and speak with their health care providers to determine the best course of action.